FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079666724> ?p ?o ?g. }

• W2079666724 endingPage "e0123761" @default.
• W2079666724 startingPage "e0123761" @default.
• W2079666724 abstract "Objective Pancreatic cancer is an aggressive tumor and the prognosis remains poor. Therefore, development of more effective therapy is needed. We previously reported that 89Zr-labeled TSP-A01, an antibody against transferrin receptor (TfR), is highly accumulated in a pancreatic cancer xenograft, but not in major normal organs. In the present study, we evaluated the efficacy of radioimmunotherapy (RIT) with 90Y-TSP-A01 in pancreatic cancer mouse models. Methods TfR expression in pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2) was evaluated by immunofluorescence staining. 111In-labeled anti-TfR antibodies (TSP-A01, TSP-A02) were evaluated in vitro by cell binding assay with the three cell lines and by competitive inhibition assay with MIAPaCa-2. In vivo biodistribution was evaluated in mice bearing BxPC-3 and MIAPaCa-2 xenografts. Tumor volumes of BxPC-3 and MIAPaCa-2 were sequentially measured after 90Y-TSP-A01 injection and histological analysis of tumors was conducted. Results MIAPaCa-2 cells showed the highest TfR expression, followed by AsPC-1 and BxPC-3 cells. 111In-TSP-A01 and 111In-TSP-A02 bound specifically to the three cell lines according to TfR expression. The dissociation constants for TSP-A01, DOTA-TSP-A01, TSP-A02, and DOTA-TSP-A02 were 0.22, 0.28, 0.17, and 0.22 nM, respectively. 111In-TSP-A01 was highly accumulated in tumors, especially in MIAPaCa-2, but this was not true of 111In-TSP-A02. The absorbed dose for 90Y-TSP-A01 was estimated to be 8.3 Gy/MBq to BxPC-3 and 12.4 Gy/MBq to MIAPaCa-2. MIAPaCa-2 tumors treated with 3.7 MBq of 90Y-TSP-A01 had almost completely disappeared around 3 weeks after injection and regrowth was not observed. Growth of BxPC-3 tumors was inhibited by 3.7 MBq of 90Y-TSP-A01, but the tumor size was not reduced. Conclusion 90Y-TSP-A01 treatment achieved an almost complete response in MIAPaCa-2 tumors, whereas it merely inhibited the growth of BxPC-3 tumors. 90Y-TSP-A01 is a promising RIT agent for pancreatic cancer, although further investigation is necessary to improve the efficacy for the radioresistant types like BxPC-3." @default.
• W2079666724 created "2016-06-24" @default.
• W2079666724 creator A5001743219 @default.
• W2079666724 creator A5010320626 @default.
• W2079666724 creator A5017677055 @default.
• W2079666724 creator A5020461673 @default.
• W2079666724 creator A5030574164 @default.
• W2079666724 creator A5035001561 @default.
• W2079666724 creator A5038612225 @default.
• W2079666724 creator A5078877030 @default.
• W2079666724 creator A5087139089 @default.
• W2079666724 date "2015-04-20" @default.
• W2079666724 modified "2023-10-16" @default.
• W2079666724 title "Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models" @default.
• W2079666724 cites W1570177179 @default.
• W2079666724 cites W1594793726 @default.
• W2079666724 cites W1815150347 @default.
• W2079666724 cites W1968762000 @default.
• W2079666724 cites W1968812902 @default.
• W2079666724 cites W1977699038 @default.
• W2079666724 cites W1982129404 @default.
• W2079666724 cites W1984398166 @default.
• W2079666724 cites W1994584379 @default.
• W2079666724 cites W2005595167 @default.
• W2079666724 cites W2006461861 @default.
• W2079666724 cites W2027437657 @default.
• W2079666724 cites W2033520317 @default.
• W2079666724 cites W2041521061 @default.
• W2079666724 cites W2052275340 @default.
• W2079666724 cites W2054429495 @default.
• W2079666724 cites W2058426435 @default.
• W2079666724 cites W2070128714 @default.
• W2079666724 cites W2073371856 @default.
• W2079666724 cites W2076614074 @default.
• W2079666724 cites W2078972803 @default.
• W2079666724 cites W2079142824 @default.
• W2079666724 cites W2079888525 @default.
• W2079666724 cites W2094108414 @default.
• W2079666724 cites W2099390343 @default.
• W2079666724 cites W2107441200 @default.
• W2079666724 cites W2130742694 @default.
• W2079666724 cites W2137463464 @default.
• W2079666724 cites W2138501321 @default.
• W2079666724 cites W2148193465 @default.
• W2079666724 cites W2152183134 @default.
• W2079666724 cites W2154261604 @default.
• W2079666724 cites W2169816791 @default.
• W2079666724 cites W2169961966 @default.
• W2079666724 cites W2219978888 @default.
• W2079666724 cites W2277732534 @default.
• W2079666724 cites W4244578979 @default.
• W2079666724 cites W1813146793 @default.
• W2079666724 doi "https://doi.org/10.1371/journal.pone.0123761" @default.
• W2079666724 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4404254" @default.
• W2079666724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25893775" @default.
• W2079666724 hasPublicationYear "2015" @default.
• W2079666724 type Work @default.
• W2079666724 sameAs 2079666724 @default.
• W2079666724 citedByCount "28" @default.
• W2079666724 countsByYear W20796667242016 @default.
• W2079666724 countsByYear W20796667242017 @default.
• W2079666724 countsByYear W20796667242018 @default.
• W2079666724 countsByYear W20796667242019 @default.
• W2079666724 countsByYear W20796667242020 @default.
• W2079666724 countsByYear W20796667242021 @default.
• W2079666724 countsByYear W20796667242022 @default.
• W2079666724 countsByYear W20796667242023 @default.
• W2079666724 crossrefType "journal-article" @default.
• W2079666724 hasAuthorship W2079666724A5001743219 @default.
• W2079666724 hasAuthorship W2079666724A5010320626 @default.
• W2079666724 hasAuthorship W2079666724A5017677055 @default.
• W2079666724 hasAuthorship W2079666724A5020461673 @default.
• W2079666724 hasAuthorship W2079666724A5030574164 @default.
• W2079666724 hasAuthorship W2079666724A5035001561 @default.
• W2079666724 hasAuthorship W2079666724A5038612225 @default.
• W2079666724 hasAuthorship W2079666724A5078877030 @default.
• W2079666724 hasAuthorship W2079666724A5087139089 @default.
• W2079666724 hasBestOaLocation W20796667241 @default.
• W2079666724 hasConcept C121608353 @default.
• W2079666724 hasConcept C126322002 @default.
• W2079666724 hasConcept C150903083 @default.
• W2079666724 hasConcept C153911025 @default.
• W2079666724 hasConcept C159654299 @default.
• W2079666724 hasConcept C185592680 @default.
• W2079666724 hasConcept C203014093 @default.
• W2079666724 hasConcept C207001950 @default.
• W2079666724 hasConcept C22814914 @default.
• W2079666724 hasConcept C2776146153 @default.
• W2079666724 hasConcept C2780210213 @default.
• W2079666724 hasConcept C32264632 @default.
• W2079666724 hasConcept C502942594 @default.
• W2079666724 hasConcept C542903549 @default.
• W2079666724 hasConcept C54355233 @default.
• W2079666724 hasConcept C55493867 @default.
• W2079666724 hasConcept C71924100 @default.
• W2079666724 hasConcept C81885089 @default.
• W2079666724 hasConcept C86803240 @default.
• W2079666724 hasConceptScore W2079666724C121608353 @default.

• next